Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says

By Blake BrittainA federal jury in California has determined that Eli Lilly NYSE:LLY must pay Nektar Therapeutics NASDAQ:NKTR $90 million for breaking an agreement related to an autoimmune drug candidate that the companies developed together, according to a Nektar filing with the US Securities and…